ArticleDiscover oncology2025
Resveratrol inhibits the progression of oral squamouscell carcinoma through Norad/Igf2bp2/Pdk1 pathway and remodeling glucose metabolism reprogramming.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Resveratrol synergizes with chloroquine to inhibit the malignant progression of oral squamous cell carcinoma by regulating KIF11.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Resveratrol in Oral Squamous Cell Carcinoma: Preclinical Evidence and Translational Opportunities.Oncology research · 2026Review
- PDK1, associated with glycolytic metabolism, is a potential prognostic biomarker in osteosarcoma.PloS one · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study investigated resveratrol impact on oral squamous cell carcinoma (OSCC) via the NORAD/IGF2BP2/PDK1 pathway.
methodsCAL-27, SCC-25, and KB cell lines were used to evaluate cell proliferation, cell cycle arrest, and protein expression. Key molecular markers were assessed using Western blot, RNA interference, and functional assays.
resultsResveratrol inhibited the growth of CAL-27, KB, and SCC-25 cancer cell lines in a dose-dependent manner, with IC50 values of 70, 145, and 125 μg/mL, respectively (P < 0.01). In CAL-27 cells, 50 μg/mL resveratrol induced G2/M arrest (P < 0.05); 100 μg/mL caused S and G2/M phase arrest (P < 0.01). Thirteen proteins changed significantly: cPKCα and Notch4 were upregulated, while p-ERK, p-PDK1, p-Cdc2, p-RB, NORAD, IGF2BP2, CDK2, Cdc2P34, Cyclin E, 14-3-3beta, and XIAP were downregulated. si-NORAD groups showed lower CAL-27 proliferation than control. IGF2BP2 silencing reduced proliferation to 69.13% in HSC3 and 74.01% in CAL-27 (P < 0.001) and decreased invasion to 72.85% and 52.44% (P < 0.001). PDK1 overexpression enhanced the proliferation and migration of hypopharyngeal cancer cells.
conclusionResveratrol inhibits OSCC proliferation, particularly in CAL-27 cells. It affects NORAD, IGF2BP2, and PDK1 pathways, altering cell cycle protein expression and causing S and G2/M phase arrest.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.